Luis Peña, Evommune CEO

Evom­mune rais­es $50M to fund clin­i­cal tri­als in skin dis­eases

Evom­mune has raised a $50 mil­lion fund­ing round that it plans to use to bankroll a se­ries of clin­i­cal tri­als over the next two years for skin dis­eases, a bet that the ex­ec­u­tive team can repli­cate the suc­cess they had at their past com­pa­nies that were sold to Big Phar­ma buy­ers.

The com­pa­ny has a Phase IIa tri­al of its ex­per­i­men­tal drug EVO101, which tar­gets IRAK4, in atopic der­mati­tis. The drug was li­censed from Eli Lil­ly af­ter the drug­mak­er made a deal for Der­mi­ra in 2020. The near­ly 120-pa­tient tri­al of the drug is slat­ed to read out this sum­mer, CEO and co-founder Luis Peña told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.